A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

Trial Profile

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Ixekizumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UNCOVER-3
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 Mar 2018 Results of post hoc analysis of three trials (NCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3).) summarizing he 12-week efficacy and safety data of Ixekizumab published in the Journal of the American Academy of Dermatology
    • 13 Mar 2018 Results assessing impact of Ixekizumab treatment on cardiovascular related parameters using Patient data from UNCOVER-1, 2, 3 trials published in the Journal of the American Academy of Dermatology
    • 12 Oct 2017 Results assessing the impact of Ixekizumab compared to etanercept (ETN) and placebo (PBO) on itch and HRQoL after 12 weeks presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top